In the past week, IBRX stock has gone down by -2.06%, with a monthly decline of -16.67% and a quarterly surge of 7.55%. The volatility ratio for the week is 5.21%, and the volatility levels for the last 30 days are 7.92% for ImmunityBio Inc The simple moving average for the past 20 days is -2.16% for IBRX’s stock, with a -31.97% simple moving average for the past 200 days.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
Additionally, the 36-month beta value for IBRX is 0.44. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IBRX is 88.78M and currently, short sellers hold a 68.63% ratio of that float. The average trading volume of IBRX on March 25, 2025 was 5.94M shares.
IBRX) stock’s latest price update
The stock price of ImmunityBio Inc (NASDAQ: IBRX) has jumped by 5.17 compared to previous close of 2.71. Despite this, the company has seen a fall of -2.06% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-07 that ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva’s market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with H.C. Wainwright repeating the rating for IBRX by listing it as a “Buy.” The predicted price for IBRX in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on March 06, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $6. The rating they have provided for IBRX stocks is “Buy” according to the report published on January 10th, 2025.
Piper Sandler gave a rating of “Neutral” to IBRX, setting the target price at $4 in the report published on May 12th of the previous year.
IBRX Trading at -7.10% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.93% of loss for the given period.
Volatility was left at 7.92%, however, over the last 30 days, the volatility rate increased by 5.21%, as shares sank -11.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.33% upper at present.
During the last 5 trading sessions, IBRX fell by -2.06%, which changed the moving average for the period of 200-days by -53.66% in comparison to the 20-day moving average, which settled at $2.91. In addition, ImmunityBio Inc saw 11.33% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -23.34 for the present operating margin
- 0.69 for the gross margin
The net margin for ImmunityBio Inc stands at -28.05. The total capital return value is set at -1.05.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated 31.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.78. The debt to equity ratio resting at -1.03. The interest coverage ratio of the stock is -2.61.
Currently, EBITDA for the company is -264.43 million with net debt to EBITDA at -1.36. When we switch over and look at the enterprise to sales, we see a ratio of 189.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.36.
Conclusion
In conclusion, ImmunityBio Inc (IBRX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
